BridgeBio Pharma, Inc. Interest Paid, Excluding Capitalized Interest, Operating Activities
BridgeBio Pharma, Inc. (BBIO) reported Interest Paid, Excluding Capitalized Interest, Operating Activities of $20.32 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:InterestPaidNet · last filed 2026-08-10
- BridgeBio Pharma, Inc. interest paid, excluding capitalized interest, operating activities for the quarter ending 2026-06-30 was $0.00.
- BridgeBio Pharma, Inc. interest paid, excluding capitalized interest, operating activities for the quarter ending 2026-03-31 was $20.32M, a 12.70% decline year-over-year.
- BridgeBio Pharma, Inc. interest paid, excluding capitalized interest, operating activities for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- BridgeBio Pharma, Inc. interest paid, excluding capitalized interest, operating activities for the quarter ending 2025-09-30 was $20.40M, a 30.12% decline year-over-year.
- BridgeBio Pharma, Inc. interest paid, excluding capitalized interest, operating activities for fiscal 2025 was $43.67M, a 52.19% decline from fiscal 2024.
- BridgeBio Pharma, Inc. interest paid, excluding capitalized interest, operating activities for fiscal 2024 was $91.34M, a 49.48% increase from fiscal 2023.
- BridgeBio Pharma, Inc. interest paid, excluding capitalized interest, operating activities for fiscal 2023 was $61.11M, a 12.24% increase from fiscal 2022.
- BridgeBio Pharma, Inc. interest paid, excluding capitalized interest, operating activities for fiscal 2022 was $54.44M, a 82.85% increase from fiscal 2021.
| Period end | Interest Paid, Excluding Capitalized Interest, Operating Activities 3 month | Interest Paid, Excluding Capitalized Interest, Operating Activities 6 month | Interest Paid, Excluding Capitalized Interest, Operating Activities 9 month | Interest Paid, Excluding Capitalized Interest, Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $20.32M 10-Q · filed 2026-08-10 | $20.32M derived: sum of 3 quarters · filed 2026-08-10 | $40.72M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $20.32M 10-Q · filed 2026-05-07 | $20.32M derived: sum of 2 quarters · filed 2026-05-07 | $40.72M derived: sum of 3 quarters · filed 2026-05-07 | $40.72M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $20.40M derived: sum of 2 quarters · filed 2026-02-24 | $20.40M derived: sum of 3 quarters · filed 2026-08-10 | $43.67M 10-K · filed 2026-02-24 |
| 2025-09-30 | $20.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $20.40M derived: sum of 2 quarters · filed 2026-08-10 | $43.67M 10-Q · filed 2025-10-29 | $56.78M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $23.27M 10-Q · filed 2026-08-10 | $36.38M derived: sum of 3 quarters · filed 2026-08-10 | $65.57M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $23.27M 10-Q · filed 2026-05-07 | $36.38M derived: sum of 2 quarters · filed 2026-05-07 | $65.57M derived: sum of 3 quarters · filed 2026-05-07 | $79.30M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $13.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $42.30M derived: sum of 2 quarters · filed 2026-02-24 | $56.03M derived: sum of 3 quarters · filed 2026-02-24 | $91.34M 10-K · filed 2026-02-24 |
| 2024-09-30 | $29.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $42.92M derived: sum of 2 quarters · filed 2025-10-29 | $78.24M 10-Q · filed 2025-10-29 | $88.52M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $13.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $49.05M 10-Q · filed 2025-08-05 | $59.33M derived: sum of 3 quarters · filed 2026-02-24 | $81.42M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $35.31M 10-Q · filed 2025-04-29 | $45.60M derived: sum of 2 quarters · filed 2026-02-24 | $67.69M derived: sum of 3 quarters · filed 2026-02-24 | $74.36M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $10.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $32.37M derived: sum of 2 quarters · filed 2026-02-24 | $39.05M derived: sum of 3 quarters · filed 2026-02-24 | $61.11M 10-K · filed 2026-02-24 |
| 2023-09-30 | $22.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $28.77M derived: sum of 2 quarters · filed 2024-11-12 | $50.83M 10-Q · filed 2024-11-12 | $57.69M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $6.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $28.74M 10-Q · filed 2024-08-01 | $35.61M derived: sum of 3 quarters · filed 2025-02-20 | $57.75M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $22.06M 10-Q · filed 2024-05-02 | $28.93M derived: sum of 2 quarters · filed 2025-02-20 | $51.07M derived: sum of 3 quarters · filed 2025-02-20 | $57.69M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $6.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $29.01M derived: sum of 2 quarters · filed 2025-02-20 | $35.63M derived: sum of 3 quarters · filed 2025-02-20 | $54.44M 10-K · filed 2025-02-20 |
| 2022-09-30 | $22.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $28.77M derived: sum of 2 quarters · filed 2023-11-02 | $47.58M 10-Q · filed 2023-11-02 | $49.11M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $6.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $25.43M 10-Q · filed 2023-08-03 | $26.97M derived: sum of 3 quarters · filed 2024-02-22 | $44.40M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $18.81M 10-Q · filed 2023-05-04 | $20.34M derived: sum of 2 quarters · filed 2024-02-22 | $37.77M derived: sum of 3 quarters · filed 2024-02-22 | $39.67M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $18.96M derived: sum of 2 quarters · filed 2024-02-22 | $20.86M derived: sum of 3 quarters · filed 2024-02-22 | $29.77M 10-K · filed 2024-02-22 |
| 2021-09-30 | $17.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $19.33M derived: sum of 2 quarters · filed 2022-11-03 | $28.24M 10-Q · filed 2022-11-03 | $30.28M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $1.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $10.81M 10-Q · filed 2022-08-04 | $12.86M derived: sum of 3 quarters · filed 2023-02-23 | $22.01M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $8.91M 10-Q · filed 2022-05-05 | $10.95M derived: sum of 2 quarters · filed 2023-02-23 | $20.11M derived: sum of 3 quarters · filed 2023-02-23 | $22.18M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $2.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $11.20M derived: sum of 2 quarters · filed 2023-02-23 | $13.27M derived: sum of 3 quarters · filed 2023-02-23 | $15.32M 10-K · filed 2023-02-23 |
| 2020-09-30 | $9.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $11.23M derived: sum of 2 quarters · filed 2021-11-04 | $13.28M 10-Q · filed 2021-11-04 | $15.04M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $2.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $4.12M 10-Q · filed 2021-08-05 | $5.88M derived: sum of 3 quarters · filed 2022-02-25 | $7.63M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $2.05M 10-Q · filed 2021-05-06 | $3.81M derived: sum of 2 quarters · filed 2022-02-25 | $5.56M derived: sum of 3 quarters · filed 2022-02-25 | $6.97M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $3.51M derived: sum of 2 quarters · filed 2022-02-25 | $4.92M derived: sum of 3 quarters · filed 2022-02-25 | $6.09M 10-K · filed 2022-02-25 |
| 2019-09-30 | $1.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $3.16M derived: sum of 2 quarters · filed 2020-11-05 | $4.34M 10-Q · filed 2020-11-05 | $5.19M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $1.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $2.58M 10-Q · filed 2020-08-11 | $3.44M derived: sum of 3 quarters · filed 2021-02-25 | |
| 2019-03-31 | $1.18M 10-Q · filed 2020-05-14 | $2.03M derived: sum of 2 quarters · filed 2021-02-25 | ||
| 2018-12-31 | $856.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $1.57M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | $718.00K 10-Q · filed 2019-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |